Cockroach Immunotherapy in Children and Adolescents

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

July 16, 2018

Primary Completion Date

June 2, 2022

Study Completion Date

June 3, 2022

Conditions
Persistent Asthma
Interventions
BIOLOGICAL

German cockroach allergenic extract

Active ingredient: a non-standardized allergen derived from the extraction and purification of proteins from German cockroach (Blattella germanica). Non-standardized glycerinated German cockroach allergenic extract is approved in the United States for diagnostic skin testing and immunotherapy by subcutaneous injection (U.S. License 467).

BIOLOGICAL

Placebo for German cockroach allergenic extract

Commercially- labeled licensed product, sterile diluent for allergenic extract (50% glycerinated), sodium bicarbonate (0.091%) sodium chloride (0.166%).

Trial Locations (11)

10029

Icahn School of Medicine at Mount Sinai, New York

10032

Columbia University Medical Center, New York

20010

Children's National Medical Center - IMPACT DC, Washington D.C.

21205

Johns Hopkins University, Baltimore

48202

Henry Ford Health System: Division of Allergy and Immunology, Detroit

60611

Ann and Robert Lurie Children's Hospital of Chicago, Chicago

63110

St. Louis Children's Hospital: Allergy, Immunology and Pulmonary Medicine Program, St Louis

80045

Children's Hospital Colorado, Aurora

02118

Boston Medical Center, Boston

45229-3039

Cincinnati Children's Hospital, Cincinnati

75390-8859

University of Texas Southwestern Medical School, Dallas

All Listed Sponsors
collaborator

Inner-City Asthma Consortium

NETWORK

collaborator

Rho Federal Systems Division, Inc.

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03541187 - Cockroach Immunotherapy in Children and Adolescents | Biotech Hunter | Biotech Hunter